Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda‐Gail Bekker, Flavia Matovu Kiweewa, Quarraisha Abdool Karim et al.|New England Journal of Medicine|2024Cited by 471